Photocure $PHO.OL breakout watch on strong Cysview expectations
Updated
Photocure PHO.OL approaching relevant resistance levels and a breakout to the upside could easily be triggered as the market cap of the company is still low.
Recent Edison analysis quote:
"Phenomenal US growth
Q418 sales in the US increased 81% to NOK18.4m and are up 50% over the course of 2018 with a clear acceleration in the second half of the year. Unit sales increased 69% during the quarter and are up 45% for the year. The total installed base of blue light cystoscopes (both rigid and flexible) increased to 157, up 51% from 104 at the beginning of 2018."
https://www.edisongroup.com/publication/rapid-acceleration-in-the-us-market/
Recent Edison analysis quote:
"Phenomenal US growth
Q418 sales in the US increased 81% to NOK18.4m and are up 50% over the course of 2018 with a clear acceleration in the second half of the year. Unit sales increased 69% during the quarter and are up 45% for the year. The total installed base of blue light cystoscopes (both rigid and flexible) increased to 157, up 51% from 104 at the beginning of 2018."
https://www.edisongroup.com/publication/rapid-acceleration-in-the-us-market/
Trade active
Uptick in trading volume in PHO tuesday, with the share pricing staying above the NOK 48 resistance/support level.RSI moving into overbought territory.
New press release today:
news.cision.com/photocure/r/photocure---better-patient-outcomes-for-patients-who-received-hexvix-,c2800300?utm_source=dlvr.it&utm_medium=twitter
Trade active
Biotech is always going to remain biotech, with all sorts of trading ongoing before Q1, but the idea is still very much active.Trade active
Photocure stock still warrants that investors could stay long, given strong fundamental news both regarding Cysview and Cevira. Key support level of NOK 40 was tested last week, but never breached.
Trade closed manually
This trade can be cancelled at this point with a nice result, though it must be noted that a new breakout watch should be initiated.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.